Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients Caregivers Providers
Log In Ask a Question
PubMed This is a summary of 17 peer-reviewed journal articles Updated
Hematology

Diagnosis and Pathology: Understanding Your Results

At a Glance

To accurately diagnose Essential Thrombocythemia (ET), a bone marrow biopsy is required alongside blood and genetic tests. This biopsy confirms the disease by revealing characteristic cell changes, checks for marrow scarring, and rules out similar blood disorders that require different care.

Understanding your pathology report is like looking at a roadmap of your disease. It isn’t just about reading high platelet counts on a blood test; it’s about evaluating the specific “look” of your bone marrow and the genetic changes driving the abnormal growth [1][2]. Getting an accurate diagnosis is critical because ET can look very similar to other conditions that have different long-term risks and treatment paths [3][4].

Why a Bone Marrow Biopsy is Necessary

While a standard blood test shows that your platelets are high, it cannot tell the doctor why they are high. A bone marrow biopsy allows a specialist (a hematopathologist) to look directly at the “factory” where your blood cells are made [5][6]. This procedure is typically performed on the back of the hip bone (the iliac crest) in an outpatient setting. Your doctor will use a local anesthetic to numb the area, which helps minimize discomfort during the quick procedure [5].

The biopsy is essential for three primary reasons:

  1. To confirm it is ET: True ET has a specific pattern of large, mature megakaryocytes (the cells that make platelets) that look like multi-lobed “staghorns” [7][8].
  2. To rule out “imposters”: Other conditions like pre-fibrotic myelofibrosis (pre-PMF) or masked Polycythemia Vera (PV) can mimic ET on blood tests but carry a higher risk of disease progression [7][9].
  3. To check for scarring: The biopsy measures fibrosis (scarring) in the marrow. Most ET patients have a “Grade 0” (no scarring), which is a very positive prognostic sign [8][10].

Differentiating ET from Other Conditions

Your doctor must rule out several other possibilities before cementing a diagnosis of ET:

  • Reactive Thrombocytosis: This is a high platelet count caused by something outside the bone marrow, such as iron deficiency, surgery, tissue damage, or an infection. It is not a blood cancer and usually resolves when the underlying cause is treated [11].
  • Pre-fibrotic Myelofibrosis (pre-PMF): This condition can look identical to ET on a standard blood test. However, under a microscope, the bone marrow shows “cloud-like” or “atypical” cells and carries a significantly higher risk of developing into full myelofibrosis over time [7][8][4].
  • Masked Polycythemia Vera (PV): Some patients have the genetic markers of PV, but their red blood cell counts aren’t quite high enough yet to meet the standard PV criteria. Distinguishing this is important because PV has a higher inherent risk of blood clots [12][5].

Your Pathology Completeness Checklist

A complete and accurate diagnosis of ET should include the following components in your medical record. If any of these are missing from your reports, it is worth discussing with your hematologist:

Component What It Tells You
Platelet Count Must be sustained at ≥450×109/L\geq 450 \times 10^9/L over time [11][7].
Bone Marrow Morphology Description of large, mature megakaryocytes with hyperlobulated (multi-lobed) nuclei, without significant clustering [7][13].
Fibrosis Grade Usually Grade 0 or 1 on a standard scale of 0–3 [8][10].
Driver Mutation Status Definitive results for JAK2, CALR, and MPL mutations [14][15].
Exclusion of Other Myeloid Neoplasms Confirmation that the disease does not meet criteria for CML, PV, or PMF [11][7].

Understanding “Triple-Negative” ET

If your genetic tests come back negative for JAK2, CALR, and MPL mutations, you are considered triple-negative [15]. In these cases, the bone marrow biopsy is even more crucial to physically prove that the high platelets are caused by a clonal bone marrow disease and not a reactive cause like severe iron deficiency [15][16]. Many triple-negative patients have a very stable disease and a favorable long-term prognosis [17].

Common questions in this guide

Why is a bone marrow biopsy needed for an essential thrombocythemia diagnosis?
A bone marrow biopsy allows a specialist to examine the cells making your blood directly. This procedure confirms the presence of essential thrombocythemia, rules out similar conditions, and checks for any scarring in your marrow.
What is pre-fibrotic myelofibrosis and how is it different from ET?
Pre-fibrotic myelofibrosis can look identical to ET on a standard blood test because both cause high platelets. However, a bone marrow biopsy will show differently shaped cells, and pre-fibrotic myelofibrosis carries a higher risk of progressing over time than ET.
What does it mean to be triple-negative in essential thrombocythemia?
Being triple-negative means your genetic tests did not find the three most common driver mutations associated with ET: JAK2, CALR, and MPL. In these cases, a bone marrow biopsy is essential to confirm the high platelets are from a true bone marrow disorder and not another cause like an infection.
What information should be included in my ET pathology report?
A complete pathology report for ET should include your sustained platelet count, a description of the bone marrow cells (morphology), a fibrosis or scarring grade, and the results of your genetic driver mutation tests.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Can you confirm that my biopsy shows 'staghorn' megakaryocytes rather than the 'cloud-like' ones seen in pre-fibrotic myelofibrosis?
  2. 2.What is my reticulin fibrosis grade exactly, and what does that mean for my long-term outlook?
  3. 3.Is it possible that my diagnosis is actually 'masked PV' based on my hemoglobin levels and JAK2 status?
  4. 4.If I am triple-negative, what other tests or clinical evidence did you use to confirm that this is a clonal disease and not reactive thrombocytosis?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (17)
  1. 1

    Ruxolitinib for essential thrombocythemia refractory to or intolerant of hydroxyurea: long-term phase 2 study results.

    Verstovsek S, Passamonti F, Rambaldi A, et al.

    Blood 2017; (130(15)):1768-1771 doi:10.1182/blood-2017-02-765032.

    PMID: 28827411
  2. 2

    Targets in MPNs and potential therapeutics.

    Levy G, Mambet C, Pecquet C, et al.

    International review of cell and molecular biology 2022; (366()):41-81 doi:10.1016/bs.ircmb.2021.06.004.

    PMID: 35153006
  3. 3

    Advances and challenges in the management of essential thrombocythemia.

    Birgegård G

    Therapeutic advances in hematology 2015; (6(3)):142-56 doi:10.1177/2040620715580068.

    PMID: 26137205
  4. 4

    Comparison of Clinical and Molecular Features Between Patients With Essential Thrombocythemia and Early/Prefibrotic Primary Myelofibrosis Presenting With Thrombocytosis in Taiwan.

    Kuo MC, Chuang WY, Chang H, et al.

    American journal of clinical pathology 2023; (159(5)):474-483 doi:10.1093/ajcp/aqac173.

    PMID: 36857745
  5. 5

    Essential Thrombocythemia and Polycythemia Vera: Focus on Clinical Practice.

    Tefferi A, Barbui T

    Mayo Clinic proceedings 2015; (90(9)):1283-93.

    PMID: 26355403
  6. 6

    Increased Dkk-1 plasma levels may discriminate disease subtypes in myeloproliferative neoplasms.

    Mambet C, Necula L, Mihai S, et al.

    Journal of cellular and molecular medicine 2018; (22(8)):4005-4011 doi:10.1111/jcmm.13753.

    PMID: 29975001
  7. 7

    Update from the latest WHO classification of MPNs: a user's manual.

    Passamonti F, Maffioli M

    Hematology. American Society of Hematology. Education Program 2016; (2016(1)):534-542 doi:10.1182/asheducation-2016.1.534.

    PMID: 27913526
  8. 8

    The differences of hemogram, myelogram, and driver gene mutations in classic myeloproliferative neoplasms.

    Wang J, Zhang J, Huang J, et al.

    Blood cells, molecules & diseases 2022; (97()):102698 doi:10.1016/j.bcmd.2022.102698.

    PMID: 35914897
  9. 9

    The prognostic relevance of serum lactate dehydrogenase and mild bone marrow reticulin fibrosis in essential thrombocythemia.

    Mudireddy M, Barraco D, Hanson CA, et al.

    American journal of hematology 2017; (92(5)):454-459 doi:10.1002/ajh.24689.

    PMID: 28211153
  10. 10

    Pre-PMF emerging as important subgroup of MPN.

    Gisslinger H

    Blood 2017; (129(24)):3142-3144 doi:10.1182/blood-2017-04-777805.

    PMID: 28620103
  11. 11

    Essential Thrombocythemia in Children and Adolescents.

    Putti MC, Bertozzi I, Randi ML

    Cancers 2021; (13(23)) doi:10.3390/cancers13236147.

    PMID: 34885256
  12. 12

    Distinguishing essential thrombocythemia JAK2V617F from polycythemia vera: limitations of erythrocyte values.

    Silver RT, Krichevsky S

    Haematologica 2019; (104(11)):2200-2205 doi:10.3324/haematol.2018.213108.

    PMID: 30948488
  13. 13

    Coexistence of Prefibrotic Myelofibrosis with Monoclonal Gammopathy of Undetermined Significance: A Case Report.

    Ismail OM, Amer A, Ibrahim FA, et al.

    Case reports in oncology 2021; (14(3)):1435-1440 doi:10.1159/000516746.

    PMID: 34899233
  14. 14

    Hematological relevance of JAK2 V617F and calreticulin mutations in Tunisian patients with essential thrombocythemia.

    Abdelghani M, Hammami H, Zidi W, et al.

    Journal of clinical laboratory analysis 2022; (36(8)):e24522 doi:10.1002/jcla.24522.

    PMID: 35754115
  15. 15

    Thrombotic risk correlates with mutational status in true essential thrombocythemia.

    Bertozzi I, Peroni E, Coltro G, et al.

    European journal of clinical investigation 2016; (46(8)):683-9 doi:10.1111/eci.12647.

    PMID: 27271054
  16. 16

    Triple-Negativity Identifies a Subgroup of Patients with Better Overall Survival in Essential Thrombocythemia.

    Santoro M, Accurso V, Mancuso S, et al.

    Hematology reports 2022; (14(3)):265-269 doi:10.3390/hematolrep14030037.

    PMID: 36135321
  17. 17

    Understanding triple negative myeloproliferative neoplasms: pathogenesis, clinical features, and management.

    Tharakan S, Mascarenhas J, Tremblay D

    Leukemia & lymphoma 2024; (65(2)):158-167 doi:10.1080/10428194.2023.2277674.

    PMID: 38033130

This page explains Essential Thrombocythemia (ET) pathology terminology for educational purposes. Your hematologist or hematopathologist is the best source for interpreting your specific bone marrow biopsy results.

Get notified when new evidence is published on Essential thrombocythemia.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.